Campaign for Sustainable Drug Pricing (Csrxp)

Coalition to promote lowering prescription drug prices.

Based in DC

🤖

AI Overview

With $320K in lobbying spend across 10 quarterly filings, Campaign for Sustainable Drug Pricing (Csrxp) is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2023 to 2025.

$320K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2023	$20K
2024	$100K
2025	$200K

Issues Lobbied

Medicare/Medicaid Copyright/Patent Pharmacy Taxation

Lobbying Firms

Whitmer & Worrall, LLC

Lobbyists

Martin Whitmer Thomas Worrall Erik Komendant

Government Agencies Targeted

These are the government entities that Campaign for Sustainable Drug Pricing (Csrxp) disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATE

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Copyright/Patent, Pharmacy, Taxation

Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act

Issues related to prescription drug prices. S.150 Affordable Prescriptions for Patients Act. S.935 Fair Accountability and Innovative Research Drug Pricing Act. S.1250/H.R.5958 Drug Price Transparency

Patent abuse issues. S. 150 Affordable Prescriptions for Patients Act of 2023. S. 79 Interagency Patent Coordination Act. S. 2780 Medication Affordability and Patent Integrity Act S. 142 Preserve Acce

Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ens